Rinath Jeselsohn, MD
Medical Oncology · Boston, MANPI 1396888780
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 48.6% of the total. Reporting peaked in 2019 at $14,154 and has fallen 85.8% since, to $2,013 in 2025.
Across 31 payments — averaging $936.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$14K
- Eli Lilly$6K
- GE HealthCare$4K
- Astrazeneca UK Limited$3K
- Pfizer$1K
- Caris MPI, Inc.$233
- plus $209 from 3 others
Across 56 payments — averaging $59,201 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.9M
- Genentech, Inc.$227K
- Pfizer$107K
- Stemline Therapeutics Inc.$51K
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$13,33846%
- Travel & lodging$14,60150%
- Food & beverage$1,0504%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 4 | $14,109 |
| Eli Lilly | 18 | $6,026 |
| GE HealthCare | 2 | $4,456 |
| Astrazeneca UK Limited | 1 | $2,740 |
| Pfizer | 1 | $1,260 |
| Caris MPI, Inc. | 1 | $233 |
| Novartis | 1 | $137 |
| AstraZeneca | 1 | $43 |
| F. Hoffmann-la Roche AG | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$14,109
- IBRANCE$1,260
- MI CANCER SEEK$233
- KISQALI$137
How this compares
$29,032 in reported general payments places this provider in the 70th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.